Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

Starner CI, Schafer JA, Heaton AH, Gleason PP.

J Manag Care Pharm. 2008 Jul-Aug;14(6):523-31.

2.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
3.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

4.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
5.

How safe is the use of thiazolidinediones in clinical practice?

Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN.

Expert Opin Drug Saf. 2009 Jan;8(1):15-32. doi: 10.1517/14740330802597821 . Review.

PMID:
19236215
6.

Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes--update 2008.

Rohatgi A, McGuire DK.

Cardiovasc Drugs Ther. 2008 Jun;22(3):233-40. doi: 10.1007/s10557-008-6093-z. Epub 2008 Mar 29. Review.

PMID:
18373186
7.

Pioglitazone: side effect and safety profile.

Shah P, Mudaliar S.

Expert Opin Drug Saf. 2010 Mar;9(2):347-54. doi: 10.1517/14740331003623218. Review.

PMID:
20175701
9.

The cardiovascular safety of rosiglitazone.

Ajjan RA, Grant PJ.

Expert Opin Drug Saf. 2008 Jul;7(4):367-76. doi: 10.1517/14740338.7.4.367 . Review.

PMID:
18613801
10.

Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.

Bourg CA, Phillips BB.

Ann Pharmacother. 2012 Feb;46(2):282-9. doi: 10.1345/aph.1Q400. Epub 2012 Jan 31. Review.

PMID:
22298606
11.

Considerations for management of fluid dynamic issues associated with thiazolidinediones.

Hollenberg NK.

Am J Med. 2003 Dec 8;115 Suppl 8A:111S-115S. Review.

PMID:
14678876
13.

Review article: Thiazolidinediones and heart failure.

Chaggar PS, Shaw SM, Williams SG.

Diab Vasc Dis Res. 2009 Jul;6(3):146-52. doi: 10.1177/1479164109338772. Review.

PMID:
20368206
14.

Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?

Schernthaner G, Chilton RJ.

Diabetes Obes Metab. 2010 Dec;12(12):1023-35. doi: 10.1111/j.1463-1326.2010.01262.x. Review.

PMID:
20977573
15.

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

Loke YK, Kwok CS, Singh S.

BMJ. 2011 Mar 17;342:d1309. doi: 10.1136/bmj.d1309. Review.

16.

Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.

Derosa G.

Drugs. 2010 Oct 22;70(15):1945-61. doi: 10.2165/11538100-000000000-00000. Review.

PMID:
20883052
17.

Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

Krentz A.

Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Review.

PMID:
19219860
18.

Cardiovascular risk and cardiometabolic protection: role of glitazones.

Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, Ferri C.

J Nephrol. 2008 Nov-Dec;21(6):826-35. Review.

PMID:
19034866
19.

Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.

Ryan G.

Postgrad Med. 2015;127(8):842-54. doi: 10.1080/00325481.2015.1095616. Epub 2015 Oct 5. Review.

PMID:
26436470
20.

Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.

Kappel BA, Marx N, Federici M.

Nutr Metab Cardiovasc Dis. 2015 Aug;25(8):697-705. doi: 10.1016/j.numecd.2015.06.006. Epub 2015 Jun 18. Review.

PMID:
26164634
Items per page

Supplemental Content

Write to the Help Desk